BioCentury | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 1 (LSD1; KDM1A)

...Phase I/II testing to treat acute myelogenous leukemia (AML). 4SC AG has the LSD1 inhibitor 4SC-202...
BioCentury | Jul 14, 2014
Clinical News

4SC-202: Phase I data

...I TOPAS trial in 24 patients with advanced hematological malignancies showed that 25-400 mg oral 4SC-202...
...days. 4SC-202 was generally well tolerated. The recommended Phase II dose is twice-daily 200 mg 4SC-202...
...to partner the compound before starting Phase II testing. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Product: 4SC-202...
BioCentury | Apr 18, 2011
Clinical News

4SC-202: Phase I started

...4SC began the open-label, dose-escalation, German Phase I TOPAS trial to evaluate 25-400 mg oral 4SC-202...
...days in 21-day cycles in up to 36 patients. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Product: 4SC-202...
Items per page:
1 - 3 of 3